SafeBoosC-IIIv - Does Cerebral Oximetry Monitoring Affect Renal Outcomes
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-28
SponsorSt. John's Research Institute
About this trial
Cerebral oximetry monitoring allows clinicians to optimize blood flow to the brain and oxygenation using the SafeBoosC treatment guideline. The guideline's interventions aims to stabilize blood pressure and oxygen levels.
As low blood pressure is a risk factor for the development of kidney injury, normalizing blood pressure may decrease the incidence of kidney injury in new-borns who are on ventilator.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
> 28 weeks of gestation Invasively ventilated
Disqualifiers
major anomalies
Trial design
Design model
Parallel
Treatments tested in this trial
Intervention Arm- Cerebral Oximetry + Treatment Guideline
Other interventionif the cerebral oximeter shows low values, a pre designed treatment guideline will be followed and corrective actions taken.
Treatment groups
1,000 Participants
are divided into 2 treatment groupsGroup A: Intervention Arm- Cerebral Oximetry + Treatment GuidelineExperimental treatment 1 intervention
Group B: Control Arm- standard careNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
composite outcome of death and acute kidney injury
composite outcome of death and acute kidney injury
Time frame
From randomization to discharge up to 2months of lifeSponsors and contacts
Click on the lead sponsor to view all of their trials.
St. John's Research Institute
Lead sponsor
Rigshospitalet, Denmark
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: